The efficacy of erythropoietin in the treatment of anemia in patients hospitalized in Intensive Care Unit(ICU)
Phase 3
- Conditions
- Anaemia.Anaemia, unspecified
- Registration Number
- IRCT2014071718517N1
- Lead Sponsor
- Vice Chancellor for research of Ardabil University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Inclusion criteria; age of 18 and above, Hematocrite more than 38% , Hospitalization in ICU for more than 7 days
Exclusion criteria; Uncontrolled hypertension, Uncontrolled seizure, Grade 3 and above burns, Pregnancy or breast feeding, Dialysing patients, The possibility of discharge from the hospital in less than 48 hours, Pulmonary embolism, Deep Vein Thrombosis and Chronic hypercoagolopathy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin. Timepoint: Before the intervention, daily until discharge or death. Method of measurement: with Complete blood cell count.
- Secondary Outcome Measures
Name Time Method Blood pressure. Timepoint: Daily. Method of measurement: mmHg with barometer.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie erythropoietin's efficacy in ICU anemia treatment?
How does erythropoietin compare to standard-of-care transfusions for ICU anemia management?
Which biomarkers correlate with erythropoietin response in ICU patients with unspecified anemia?
What adverse events are associated with erythropoietin use in ICU anemia trials and how are they managed?
Are there combination therapies or alternative drugs showing better outcomes than erythropoietin for ICU anemia?